News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

National Institute for Clinical Excellence (NICE) Rejects Pfizer Inc. (PFE)'s Bone Cancer Drug


7/16/2013 7:34:40 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

The UK National Institute for Health and Care Excellence (NICE) has rejected Pfizer’s new chronic myeloid leukaemia (CML) drug, Bosulif (bosutinib).

NICE chief executive Sir Andrew Dillon said there is evidence to suggest that bosutinib was considered clinically effective for the treatment of CML.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES